Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Fresh Meadows, New York Clinical Trials

A listing of Fresh Meadows, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (25) clinical trials

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate ...

Phase

1.82 miles

Learn More »

A Trial Investigating the Safety Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

During the first four weeks of the trial, participants will be randomly assigned to one of four groups: three groups will receive fixed doses of TransCon PTH and one group will receive placebo. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither ...

Phase

4.93 miles

Learn More »

HIPEC After Initial CRS in Patients Who Have Received NACT

Cancer of the ovary, fallopian tube and peritoneum (referred to as epithelial ovarian cancer, EOC) remains the leading cause of death from gynecologic cancer in the US and is expected to account for 22,000 cases and 14,000 deaths in 2016. Patients classically present with peritoneal carcinomatosis and ascites, a reflection ...

Phase

5.91 miles

Learn More »

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

Cytomegalovirus (CMV) can be transmitted from the mother to the fetus and is a leading cause of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect on language development ...

Phase

5.91 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

This pivotal Phase 3 study will determine if MEDI8897 will prevent medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy infants entering their first RSV season. The population to be enrolled is healthy late preterm and term infants born 35 weeks 0 days or greater gestational age (GA) who ...

Phase

6.78 miles

Learn More »

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

This study is a pivotal Phase 2/3 randomized, double-blind, palivizumab-controlled study to evaluate the safety, pharmacokinetics (PK), anti-drug antibody (ADA) response, and descriptive efficacy for MEDI8897 in high-risk infants eligible to receive palivizumab when entering their first or second RSV season (Season 1 or Season 2, respectively). Approximately 1,500 palivizumab-eligible ...

Phase

8.16 miles

Learn More »

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

The study will be a 10 to 12-week study, including a 1 to 3-week screening Period, followed by a double-blind, randomized, placebo-controlled, parallel-group Treatment Period, and a 1-week follow-up Period. Subjects eligible for the study will be randomized to receive either NYX-783 (4-weeks) or placebo (4 or 8-weeks).

Phase

8.65 miles

Learn More »

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC HCC and HNSCC

The primary objective of the study is to evaluate the clinical activity of neoadjuvant cemiplimab therapy in patients with resectable Non-small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), and Head and neck squamous cell carcinoma (HNSCC) lesions, as measured by pathological evaluations of resected tumors. The secondary objectives of the ...

Phase

8.68 miles

Learn More »

Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring

There is a significant incidence of recurrent AF following initial diagnosis of AF. Inclusion of left atrial (LA) and left atrial appendage (LAA) abnormalities together with risk prediction of CVA using CHA2DS2-Vasc score will identify patients at low or high risk for adverse cardiovascular events in patients with manifest and ...

Phase N/A

8.79 miles

Learn More »

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Phase

8.83 miles

Learn More »